Atnaujinkite slapukų nuostatas

El. knyga: Antiplatelet Agents

Edited by , Edited by , Edited by , Edited by
  • Formatas: PDF+DRM
  • Serija: Handbook of Experimental Pharmacology 210
  • Išleidimo metai: 23-Aug-2012
  • Leidėjas: Springer-Verlag Berlin and Heidelberg GmbH & Co. K
  • Kalba: eng
  • ISBN-13: 9783642294235
  • Formatas: PDF+DRM
  • Serija: Handbook of Experimental Pharmacology 210
  • Išleidimo metai: 23-Aug-2012
  • Leidėjas: Springer-Verlag Berlin and Heidelberg GmbH & Co. K
  • Kalba: eng
  • ISBN-13: 9783642294235

DRM apribojimai

  • Kopijuoti:

    neleidžiama

  • Spausdinti:

    neleidžiama

  • El. knygos naudojimas:

    Skaitmeninių teisių valdymas (DRM)
    Leidykla pateikė šią knygą šifruota forma, o tai reiškia, kad norint ją atrakinti ir perskaityti reikia įdiegti nemokamą programinę įrangą. Norint skaityti šią el. knygą, turite susikurti Adobe ID . Daugiau informacijos  čia. El. knygą galima atsisiųsti į 6 įrenginius (vienas vartotojas su tuo pačiu Adobe ID).

    Reikalinga programinė įranga
    Norint skaityti šią el. knygą mobiliajame įrenginyje (telefone ar planšetiniame kompiuteryje), turite įdiegti šią nemokamą programėlę: PocketBook Reader (iOS / Android)

    Norint skaityti šią el. knygą asmeniniame arba „Mac“ kompiuteryje, Jums reikalinga  Adobe Digital Editions “ (tai nemokama programa, specialiai sukurta el. knygoms. Tai nėra tas pats, kas „Adobe Reader“, kurią tikriausiai jau turite savo kompiuteryje.)

    Negalite skaityti šios el. knygos naudodami „Amazon Kindle“.

Antiplatelet therapy is the cornerstone of treatment of ischemic cardiovascular disease and over the last few years spectacular advancements in this field have been recorded. This is the first comprehensive handbook entirely dedicated to all the aspects of antiplatelet therapy. The book is divided into three main sections, pathophysiology, pharmacology and therapy, for a total of 23 chapters. A large group of leading experts from different European countries and from the USA, both from academia and industry, have contributed to the book. Besides a detailed overview on the pharmacology and clinical applications of all the currently used or of the novel antiplatelet agents, innovative approaches (e.g. intracellular signalling as an antiplatelet target, small RNAs as platelet therapeutics, etc.) or unconventional aspects (e.g. pharmacologic modulation of the inflammatory action of platelets are also treated. The book is oriented to both basic investigators and to clinicians involved with research on platelet inhibition or with the clinical use of antiplatelet therapies.

The first comprehensive handbook entirely dedicated to all the aspects of antiplatelet therapy, this work surveys pathophysiology, pharmacology and therapy. Coverage incorporates recent achievements, and includes current and novel antiplatelet agents and more.
Part I Pathophysiology
Platelets: Production, Morphology and Ultrastructure
3(20)
Jonathan N. Thon
Joseph E. Italiano
Platelet Receptors
23(36)
Alexandre Kauskot
Marc F. Hoylaerts
Platelet Signaling
59(28)
Timothy J. Stalker
Debra K. Newman
Peisong Ma
Kenneth M. Wannemacher
Lawrence F. Brass
Platelet Interaction with the Vessel Wall
87(24)
Philip G. de Groot
Rolf T. Urbanus
Mark Roest
Platelets in Atherosclerosis and Thrombosis
111(26)
Christian Schulz
Steffen Massberg
Part II Pharmacology
Aspirin and Other COX-1 Inhibitors
137(28)
Carlo Patrono
Bianca Rocca
Thienopyridines and Other ADP-Receptor Antagonists
165(34)
Isabell Bernlochner
Dirk Sibbing
Glycoprotein IIb/IIIa Antagonists
199(26)
Karen M. Hook
Joel S. Bennett
Targeting Phosphodiesterases in Anti-platelet Therapy
225(14)
Matthew T. Rondina
Andrew S. Weyrich
PAR-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Atherothrombosis
239(22)
Sergio Leonardi
Richard C. Becker
Thromboxane Receptors Antagonists and/or Synthase Inhibitors
261(26)
Giovanni Davi
Francesca Santilli
Natale Vazzana
Inhibitors of the Interaction Between von Willebrand Factor and Platelet GPIb/IX/V
287(24)
Paolo Gresele
Stefania Momi
Inhibitors of the Interactions Between Collagen and Its Receptors on Platelets
311(28)
Hans Deckmyn
Simon F. De Meyer
Katleen Broos
Karen Vanhoorelbeke
Intracellular Signaling as a Potential Target for Antiplatelet Therapy
339(30)
Patrick Andre
Novel Targets for Platelet Inhibition
369(26)
Kathleen Freson
Chris Van Geet
Variability of Platelet Indices and Function: Acquired and Genetic Factors
395(40)
Giovanni de Gaetano
Iolanda Santimone
Francesco Gianfagna
Licia Iacoviello
Chiara Cerletti
Small RNAs as Potential Platelet Therapeutics
435(12)
Leonard C. Edelstein
Paul F. Bray
Pharmacological Modulation of the Inflammatory Actions of Platelets
447(24)
Richard Amison
Clive Page
Simon Pitchford
Part III Therapy
The Role of Laboratory Monitoring in Antiplatelet Therapy
471(24)
Marco Cattaneo
Antiplatelet Agents in Ischemic Heart Disease
495(24)
Christopher H. May
A. Michael Lincoff
Antiplatelet Therapy in Cerebrovascular Disorders
519(28)
Ralph Weber
Johannes Brenck
Hans-Christoph Diener
Antiplatelet Therapy in Peripheral Artery Disease
547(18)
Francesco Violi
Stefania Basili
Jeffrey S. Berger
William R. Hiatt
Primary Prevention of Ischaemic Cardiovascular Disorders with Antiplatelet Agents
565(42)
Tom Meade
Index 607